**Core tip:** Whether perioperative blood loss or blood transfusion has adverse effects on the prognosis in patients with gastric cancer remains unclear. We reviewed laboratory and clinical evidence of this association in patients with gastric cancer. A large amount of clinical evidence revealed that excessive intraoperative blood loss and blood transfusion have adverse effects on the prognosis. The possible mechanisms underlying the association between intraoperative blood loss and a poor prognosis are immunosuppression, unfavorable postoperative conditions, and tumor cell spillage into the pelvis, and those underlying the association between blood transfusions and a poor prognosis are immunosuppression and preoperative anemia.

INTRODUCTION
============

Surgical resection is still the most promising avenue for patients with resectable gastric cancer. However, it sometimes induces excessive intraoperative blood loss (IBL) and requires perioperative allogeneic blood transfusion (BTF), especially when gastrectomy with systematic lymph node dissection is performed. Furthermore, as IBL becomes more excessive, the need for BTF further increases; thus, IBL is closely associated with BTF.

There are lasting discussions and controversies about whether IBL or BTF has adverse effects on the prognosis in patients with gastric cancer\[[@B1]-[@B3]\]. Patients requiring BTF often have severe illness, advanced cancer, a poor general condition, and a higher prevalence of comorbidities, and these confounding factors themselves induce postoperative complications, surgical death, and a worse prognosis\[[@B4]-[@B6]\]. The same is true of IBL. Thus, it is difficult to evaluate whether IBL or BTF itself has adverse effects on the prognosis. However, clinical trials that determine these effects in surgical treatment are not ethically permissible. We therefore reviewed clinical and laboratory evidence to explore the effects of IBL and BTF on the prognosis of patients with gastric cancer.

MECHANISM OF ADVERSE EFFECT OF IBL
==================================

There are three possible causes of the adverse effect of IBL on the prognosis: Anti-tumor immunosuppression induced by IBL, an unfavorable postoperative condition induced by IBL, and spillage of microscopic cancer cells in the pelvic cavity *via* the blood lost during IBL. These mechanisms are summarized in Figure [1](#F1){ref-type="fig"}.

![The mechanism of adverse effect of intraoperative blood loss and perioperative blood transfusion. IBL: Intraoperative blood loss; BTF: Blood transfusion.](WJG-25-2743-g001){#F1}

First, many studies have shown that the main cause of the adverse effect of excessive IBL is anti-tumor immunosuppression *via* the loss of plasma con-stituents\[[@B7]-[@B10]\]. In support of this concept, several studies have revealed that the prevalence of hematogenous recurrence, which is correlated with immuno-suppression, was significantly higher in patients with excessive IBL\[[@B9],[@B10]\]. However, these studies did not demonstrate the mechanism. Bruns et al\[[@B11]\] reported that IBL of \> 700 mL during gastrointestinal surgery was associated with a significant decrease in natural killer cell activity, leading to an unfavorable prognosis. Miki et al\[[@B12]\] reported that interleukin (IL)-6 and tumor growth factor triggered by IL-6 were increased in patients with colorectal cancer receiving BTF due to excessive IBL. Thus, the mechanism of immunosuppression in gastric cancer surgery is speculative, and laboratory evidence is lacking. A validation study is therefore needed.

Second, excessive IBL may lead to an unfavorable postoperative condition, such as the development of postoperative complications, thus adversely affecting the prognosis\[[@B9],[@B13]\]. Postoperative complications occur may lead to severe tissue damage caused by local and generalized inflammatory reactions, resulting in more severe immunosuppression\[[@B13]\].

Third, Kamei et al\[[@B14]\] reported that excessive IBL is an independent risk factor for peritoneal recurrence after curative gastrectomy. They suggested the possibility that blood loss into the peritoneal cavity may promote tumor spillage during surgery, which may be specifically associated with peritoneal recurrence. Arita et al\[[@B15]\] further confirmed the association between IBL and peritoneal recurrence in the laboratory setting. Although this idea is very interesting, no other study to date has supported this hypothesis. Moreover, it is unclear whether this adverse effect remains when administering S-1 monotherapy which is one of the standard postoperative adjuvant chemotherapies that mainly suppresses peritoneal recurrence\[[@B16]\]. Therefore, further analysis in the clinical practice setting is needed.

LITERATURE SEARCH OF STUDIES REPORTING EFFECT OF IBL ON PROGNOSIS
=================================================================

Our investigation of the relationship between IBL and the prognosis was derived from that of patients with colorectal cancer. Heiss et al\[[@B17]\] first reported the possibility that IBL itself may be beneficial for survival of malignant cells in the host and also found a positive link with tumor recurrence and poor outcomes in patients with colorectal cancer. The adverse effect of IBL on the prognosis in patients with gastric cancer was first reported by Dhar et al\[[@B7]\] in 2000. We have summarized the studies reporting the effect of IBL on the prognosis in Table [1](#T1){ref-type="table"}. Dhar et al\[[@B7]\] reported that IBL of \> 500 mL was an independent predictor of survival in an analysis of 152 patients with transmural (T2N0--T3N2) gastric cancer. They hypothesized that IBL reduced the body's immunity and its ability to fight cancer cells; this concept was quoted from the report by Bruns et al\[[@B11]\]. However, Dhar et al\[[@B7]\] provided no information on perioperative BTF, which is a strong confounding factor for the prognosis. Similar studies were subsequently reported. Kamei et al\[[@B14]\] reported that IBL of ≥ 475 mL was specifically associated with the development of peritoneal recurrence in 146 patients who underwent curative gastrectomy for advanced gastric cancer. They reported for the first time the relationship between IBL and the recurrence pattern. Liang et al\[[@B8]\] also reported that IBL of ≥ 200 mL was an independent prognostic factor in 845 patients who underwent curative gastrectomy. In their study, IBL of ≥ 200 mL was a prognostic factor even when patients who underwent BTF were excluded; however, BTF administration was not a prognostic factor. Mizuno et al\[[@B9]\] reported that IBL of ≥ 400 mL was a significant predictor of survival and cancer recurrence in 203 patients with stage II/III gastric cancer and was associated with the prevalence of hematogenous recurrence. Their study excluded patients who received BTF to eliminate a potential confounding bias caused by the adverse effects of BTF. Ito et al\[[@B10]\] reported that IBL of \> 330 mL had an adverse effect on the long-term prognosis in 1013 patients with stage II/III gastric cancer. Their study also excluded patients who received BTF and was the largest-scale study, thoroughly eliminating complicated confounding factors. IBL is closely associated with BTF administration, and the prognostic significance of IBL might be masked by the adverse effect of BTF. From this viewpoint, three studies\[[@B8]-[@B10]\] excluded this confounding influence, indicating that IBL itself has an adverse effect on the long-term prognosis in patients with gastric cancer.

###### 

Studies of effects of intraoperative blood loss on prognosis in patients with gastric cancer

  **Study**                       **Period**   **Sample size**   **Selected group**        **Amount of IBL**   **Patients received BTF**   **Adverse effect of BTF on prognosis**   **Adverse effect of IBL on prognosis**
  ------------------------------- ------------ ----------------- ------------------------- ------------------- --------------------------- ---------------------------------------- ----------------------------------------
  Dhar et al\[[@B7]\], 2000       1979-1989    152               T2N0--T3N2                \> 500 ml           Not specified               \-                                       Yes (Survival)
  Kamei et al\[[@B14]\], 2009     1992-2003    146               Curative Gastrectomy      ≥ 475 mL            Included (13%)              No (Peritoneal recurrence)               Yes (Peritoneal recurrence)
  Liang et al\[[@B8]\], 2013      2003-2007    845               stage I-III               ≥ 200 ml            Included (25%)              No (Survival)                            Yes (Survival)
  Ishino et al\[[@B18]\], 2014    2001-2012    214               Laparoscopic,stage I-II   ≥ 1% body weight    0%                          \-                                       Yes (Survival)
  Arita et al\[[@B15]\], 2015     1997-2012    540               Curative Gastrectomy      \> 326 ml           Not specified               \-                                       Yes (Peritoneal recurrence)
  Mizuno et al\[[@B9]\], 2016     1999-2015    203               stage II/III              ≥ 400 mL            Not specified               \-                                       Yes (Survival, Recurrence)
  Ito et al\[[@B10]\], 2018       2010-2014    1013              stage II/III              \> 330 mL           Not specified               \-                                       Yes (Recurrence)
  Ojima et al\[[@B19]\], 2009     1991-2002    856               Curative gastrectomy      ≥ 1000 mL           Included (18%)              Yes (Survival)                           No (Survival)
  Squires et al\[[@B20]\], 2015   2000-2012    765               Curative gastrectomy      \> 250 mL           Included (22%)              Yes (Survival, Recurrence)               No (Survival, Recurrence)
  Kanda et al\[[@B6]\], 2016      1999-2014    250               stage II/III              ≥ 800 mL            Included (23%)              Yes (Survival, Recurrence)               No (Survival)

IBL: Intraoperative blood loss; BTF: Blood transfusion.

Evidence was also found in the field of laparoscopic surgery. Ishino et al\[[@B18]\] reported that IBL of ≥ 1% body weight was significantly correlated with postoperative complications and was an independent predictor of survival in 214 patients who underwent laparoscopy-assisted gastrectomy for gastric cancer. Conversely, several negative studies of the adverse effects of IBL on the prognosis have also been published (summarized in Table [1](#T1){ref-type="table"}). Ojima et al\[[@B19]\] reported that BTF administration was an independent prognostic factor for survival in 856 patients who underwent curative gastrectomy but that IBL of ≥ 1000 mL was not a prognostic factor. Likewise, two studies showed that BTF administration was an independent prognostic factor for survival but that excessive IBL was not prognostic factor\[[@B6],[@B20]\]. However, the threshold of the IBL volume in these reports was greatly different, and neither study excluded the confounding influence of BTF.

SUMMARY OF EFFECT OF IBL ON PROGNOSIS
=====================================

The accumulation of clinical evidence reveals that excessive IBL may have adverse effects on the prognosis in patients with gastric cancer by promoting anti-tumor immunosuppression, unfavorable postoperative conditions, and a specific association with peritoneal recurrence by spillage of cancer cells into the pelvic cavity during surgery. However, the laboratory evidence is weak and some issues remain unclear. IBL thresholds varied, and the results might differ depending on these thresholds. A higher threshold for the amount of IBL would introduce more confounding factors (*e.g*., BTF, postoperative anemia, and postoperative complications). Another issue is that only two studies have reported the relationship between IBL and peritoneal recurrence.

MECHANISM OF ADVERSE EFFECT OF BTF
==================================

There are two possible causes of the adverse effect of BTF on the prognosis: anti-tumor immunosuppression induced by BTF and patient-related confounding factors (*e.g*., preoperative anemia and postoperative complications). These factors are associated with a worse prognosis and higher requirement for perioperative BTF. These mechanisms are summarized in Figure [1](#F1){ref-type="fig"}.

Gantt\[[@B21]\] was the first to report the possibility of promoting tumor growth by immunosuppression due to BTF in 1981. Numerous authors have since considered that BTF administration has profound adverse effects on the host's immune system\[[@B22]-[@B25]\]. Mechanisms of inhibition of host immunity by BTF are diverse and include cytokine-mediated immune responses and suppression of cellular and humoral immunity against cancer cells. BTF-induced immunomodulatory effects drive the immune system to inhibit IL-2 production\[[@B25]\], decrease interferon gamma\[[@B23]\], suppress natural killer cell function\[[@B24]\], release immunosuppressive prostaglandins\[[@B25]\], decrease monocyte activity\[[@B25]\], and increase of regulatory T cells (suppressor T cells)\[[@B24]-[@B27]\].

BTF administration also promotes increases in IL-6\[[@B12]\], vascular endothelial growth factor\[[@B28]\], and hepatocyte growth factor\[[@B29]\], which play fundamental roles in tumor growth, malignant transformation, and invasion of tumor cells\[[@B30],[@B31]\]. Additionally, in patients with gastric cancer, overexpression of these cytokines is reportedly correlated with a poor prognosis\[[@B12],[@B32]-[@B34]\]. The immunosuppression caused by BTF creates favorable conditions for tumor growth; additionally, BTF increases the risk of postoperative complications\[[@B3]\], which also have adverse effects on the prognosis\[[@B13]\].

However, some issues remain unclear. The type of blood products received (*e.g*., red blood cells, leukodepleted blood, whole blood) was not constant among studies. The disorder observed after BTF administration is caused by the presence of leukocytes and their products, as mentioned above. Current BTF products are often leukodepleted, and filtered transfusion is routinely performed; thus, the conta-mination of cytokines is decreased and the effect is weakened. In contrast to this concept, no difference in the prognosis was found in comparative studies between leukocyte-depleted blood and non-leukocyte-depleted blood\[[@B35],[@B36]\]. The roles of these cytokines and growth factors in current transfusion treatment remain unclear.

Preoperative anemia, which is a patient-related confounding factor, is another possible cause of a worse prognosis in patients with malignancy\[[@B17]\]. Gastrointestinal tumors sometimes bleed due to the passage of intestinal contents and the effect of digestive juices, and this bleeding may lead to anemia. In particular, once anemia has occurred in patients of advanced age, it persists because of these patients' physiological decrease in hematopoietic cells in the bone marrow, decrease in hematopoietic stem cells, and reduced serum erythropoietin levels due to renal impairment\[[@B37]\]. Additionally, continuous anemia causes malnutrition, which also has adverse effects on the prognosis\[[@B38]\]. Numerous prospective and retrospective studies have shown that patients with preoperative anemia have a worse prognosis than patients without anemia\[[@B39]\]. Hence, preoperative anemia is a cause of the requirement for BTF, which itself also has adverse effects on the prognosis.

Although we have summarized the mechanisms of adverse effects of BTF, some unmeasurable and non-excludable confounding factors remain. Surgical damage is one such factor and can also lead to severe immunosuppression. The degree of surgical damage depends on the surgical organ. Surgical damage induced during colon cancer surgery is considered to be relatively mild, and there are many negative reports on the influence of BTF on the prognosis of such patients\[[@B40],[@B41]\]. However, surgical damage induced during esophageal cancer surgery is considered to be relatively severe, and there are many positive reports on the influence of BTF on the prognosis of such patients\[[@B42],[@B43]\]. In gastric cancer surgery, the degree of surgical damage varies greatly depending on the operation type; therefore, it may be more effective to investigate this issue according to the operation type (total gastrectomy *vs* distal gastrectomy, open surgery *vs* laparoscopic surgery).

LITERATURE SEARCH OF STUDIES REPORTING EFFECT OF BTF ON PROGNOSIS
=================================================================

Many studies have been performed to evaluate the adverse effect of perioperative BTF on the prognosis in patients with gastric cancer, and we have summarized these studies in Table [2](#T2){ref-type="table"}. Kaneda et al\[[@B44]\] first reported that BTF administration had an adverse effect on survival in 231 patients who underwent curative gastrectomy. Ojima et al\[[@B19]\] subsequently reported that BTF administration was an independent prognostic factor for survival in 856 patients who underwent curative gastrectomy, even when the amount of transfused blood was small. Kanda et al\[[@B6]\] reported that BTF administration was an independent prognostic factor for survival and recurrence in patients with stage II/III gastric cancer, regardless of the volume of BTF. They also reported that the prognostic impact of BTF became less clear after introduction of adjuvant chemotherapy with S-1. Three systematic reviews and meta-analyses support the idea that BTF is associated with a worse prognosis, all-cause mortality, cancer-related mortality, and recurrence (summarized in Table [3](#T3){ref-type="table"}).

###### 

Studies of effects of blood transfusion on prognosis in patients with gastric cancer

  **Study**                          **Period**   **Sample size**   **Selected group**     **Rates of received BTF**   **Timing of transfusions**   **Adverse effect of BTF on prognosis**
  ---------------------------------- ------------ ----------------- ---------------------- --------------------------- ---------------------------- ----------------------------------------
  Kaneda et al\[[@B44]\], 1987       1976-1980    231               Not specified          51%                         Not specified                Yes (Survival)
  Ojima et al\[[@B19]\], 2009        1991-2002    856               Curative gastrectomy   18%                         Pre + Intra + Post           Yes (Survival)
  Squires et al\[[@B20]\], 2015      2000-2012    765               Curative gastrectomy   22%                         Intra + Post                 Yes (Survival, Recurrence)
  Kanda et al\[[@B6]\], 2016         1999-2014    250               stage II /III          23%                         Pre + Intra + Post           Yes (Survival, Recurrence)
  Kampschoer et al\[[@B45]\], 1989   1976-1981    1000              Curative gastrectomy   37%                         Pre + Intra + Post           No (Survival)
  Kamei et al\[[@B14]\], 2009        1992-2003    146               Curative gastrectomy   13%                         Not specified                No (Peritoneal recurrence)
  Pacelli et al\[[@B46]\], 2011      1990-2005    927               Curative gastrectomy   35%                         Pre + Intra + Post           No (Survival)
  Liang et al\[[@B8]\], 2013         2003-2007    845               stage I-III            25%                         Pre + Intra + Post           No (Survival)
  Rausei et al\[[@B47]\], 2013       1995-2011    224               stage I-III            20%                         Pre + Intra + Post           No (Survival)

BTF: Blood transfusion; Pre: Preoperative; Intra: Intraoperative; Post: Postoperative.

###### 

Systematic reviews and meta-analyses of effects of blood transfusion on prognosis in patients with gastric cancer

  **Study**                    **Rate of received**   **Adverse effect on OS**   **Adverse effect on CSS**   **Adverse effect on RFS**   **Adverse effect on PCs**
  ---------------------------- ---------------------- -------------------------- --------------------------- --------------------------- ---------------------------
  Sun et al\[[@B1]\], 2015     36.3%                  Yes,                       Yes,                        Yes,                        Not specified
  HR, 2.17;                    HR, 2.57;              HR, 1.52;                                                                          
  95%CI, 1.86-2.37             95%CI, 1.24-5.34       95%CI, 1.08-2.15                                                                   
  Li et al\[[@B2]\], 2015      44.8%                  Yes,                       Not specified               Yes,                        Yes,
  HR, 1.26;                                                                                                                              
  HR, 1.36;                    HR, 3.33;                                                                                                 
  95 % CI, 1.21-1.31                                                                                                                     
  95%CI, 1.02-1.81             95%CI, 1.02-1.81                                                                                          
  Agnes et al\[[@B3]\], 2018   Not specified          Yes,                       Yes,                        Yes,                        Yes,
  HR, 1.34;                    HR, 1.66;              HR, 1.48;                  HR, 1.36;                                               
  95%CI, 1.23-1.45             95%CI, 1.50-2.19       95%CI, 1.18-1.86           95%CI, 2.10-5.29                                        

BTF: Blood transfusion; OS: Overall survival; CSS: Cancer-specific survival; RFS: Relapse-free survival; PCs: Postoperative complications; HR: Hazard ratio; CI: Confidence interval.

However, some studies have shown that BTF does not have an adverse effect on the prognosis (summarized in Table [2](#T2){ref-type="table"}). Kampschöer et al\[[@B45]\] performed a large-scale retrospective study and found that the survival of patients who had undergone BTF was shorter than that of patients who had not undergone BTF; however, after stratifying patients into stages and applying proportional regression analyses, BTF administration did not appear to have any effect on the prognosis but was instead associated with other prognostic features. Pacelli et al\[[@B46]\] conducted a multicenter retrospective study and reported that BTF had a slight, but not significant, adverse effect on survival of 927 patients who underwent curative gastrectomy.

SUMMARY OF EFFECT OF BTF ON PROGNOSIS
=====================================

The adverse effects of BTF have been well verified by clinical and laboratory data; these adverse effects are caused by anti-tumor immunosuppression and patient-related confounding factors that lead to a requirement for BTF. However, this information may not be helpful in the clinical setting because BTF is still required in the event of massive bleeding during surgery or preoperative anemia. However, there may be room for consideration such as adjusting preoperative anemia and paying attention so as not to lead postoperative complications.

REMAINING PROBLEMS FOR FUTURE STUDIES
=====================================

The adverse effects of IBL or BTF were previously ascertained by clinical evidence. However, continuous and untiring efforts to minimize IBL and surgical damage have been progressing (*i.e*., development of laparoscopic surgery, improvements in surgical techniques and devices, and enhanced recovery after surgery programs), and the amount of IBL and frequency of BTF administration have been decreasing. In addition, perioperative chemotherapy has been further developed, helping to prolong survival. Further accumulation of data and performance of high-quality studies are required to clarify whether IBL or BTF still have adverse effects on the prognosis.

CONCLUSION
==========

IBL and BTF lead to adverse effects on the prognosis in patients with gastric cancer, and the main causes are anti-tumor immunosuppression and confounding factors such as postoperative complications and preoperative anemia. Surgeons should make efforts to minimize IBL and BTF to improve patients' prognosis.
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